荃信生物(02509.HK) 公布,近期,公司自主研发的长效双抗QX027N注射液获得中国国家药品监督管理局药品审评中心的临床试验默示许可,分别拟用于治疗慢性阻塞性肺疾病(COPD)及慢性鼻窦炎伴鼻息肉(CRSwNP)。本次获批是QX027N继特应性皮炎(AD)及哮喘后新增的两项呼吸系统相关适应症。(sl/u)(港股报价延迟最少十五分钟。)AASTOCKS新闻
Source Link荃信生物(02509.HK) 公布,近期,公司自主研发的长效双抗QX027N注射液获得中国国家药品监督管理局药品审评中心的临床试验默示许可,分别拟用于治疗慢性阻塞性肺疾病(COPD)及慢性鼻窦炎伴鼻息肉(CRSwNP)。本次获批是QX027N继特应性皮炎(AD)及哮喘后新增的两项呼吸系统相关适应症。(sl/u)(港股报价延迟最少十五分钟。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.